European journal of medical research · 2013 · 69 citations · 24 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunoregulationInnate ImmunityCancer EpigeneticsEpigenetic Regulation In CancerExosome AnalysisImmuno-oncology BiomarkersTumor AntigensTumor-associated AntigensExosome Protein BiomarkersExosome-based TherapyExosomesExosomes In CancerImmune Modulation By Extracellular VesiclesImmunostimulatory PathwaysTumor-derived ExosomesWestern Blot Analysis
BACKGROUND: Tumor-derived exosomes have been viewed as a source of tumor antigens that can be used to induce anti-tumor immune responses. In the current study, we aim to investigate the regulatory effect of the epigenetic drug MS-275 on hepatoma G2 (HepG2) cell-derived exosomes, especially for their immunostimulatory properties and alteration of some non-specific immune protein expression, such as heat shock protein (HSP) 70, major histocompatibility complex (MHC) class I polypeptide-related sequence A (MICA) and MICB. METHODS: MS-275 was used to modulate the secretion of exosomes in human HepG2 cells, and exosomes from untreated HepG2 cells served as negative controls. RT-PCR was used to test the expression of HSP70, MICA and MICB in HepG2 cells. Immunogold labeling of exosomes and western blotting analysis were carried out to compare the expression of HSP70, MICA and MICB proteins in exosomes with or without MS-275 treatment. A natural killer (NK) cell cytotoxicity assay and peripheral blood mononuclear cell (PBMC) proliferation assay were used to evaluate the effect of MS-275 on the immunostimulatory ability of exosomes. RESULTS: Immunogold labeling and western blot analysis showed that modification of MS-275 increased the expression of HSP70 and MICB in exosomes. RT-PCR showed the mRNA levels of HSP70 and MICB were upregulated in HepG2 cells and were consistent with their protein levels in exosomes. The exosomes modified by MS-275 could significantly increase the cytotoxicity of NK cells and proliferation of PBMC (P < 0.05). CONCLUSIONS: The non-specific immune response of exosomes derived from HepG2 cells could be enhanced with treatment by the histone deacetylase inhibitor (HDACi) drug MS-275; this could provide a potential tumor vaccine strategy against liver cancer.
24
Fanny Chalmin, Sylvain Ladoire, Grégoire Mignot et al. · Journal of Clinical Investigation · 2010 · 987 citations · Full text
Medicine, Immunology, Oncology +16
Cells release prions in association with exosomes
Benoît Février, Didier Vilette, Fabienne Archer et al. · Proceedings of the National Academy of Sciences · 2004 · 983 citations · Full text